Is screening for thrombophilia cost-effective?

Current Opinion in Hematology

Volumn 14, Issue 5, 2007, Pages 500-503

  Wu, Olivia ^a   Greer, Ian A ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Cost effectiveness; Screening; Thrombophilia; Venous thromboembolism

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

BLOOD CLOTTING TEST; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; EVIDENCE BASED PRACTICE; FAMILY HISTORY; HEALTH CARE COST; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; MASS SCREENING; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

CONTRACEPTIVES, ORAL; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MASS SCREENING; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 34648827563     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32825f5318     Document Type: Review

References (17)

1. Walker ID, Greaves M, Preston FE, on behalf of the Haemostasis and Thrombosis Task Force British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114:512-528.
2. Greaves M, Baglin T. Laboratory testing for heritable thrombophilia: impact on clinical management of thrombotic disease. Br J Haematol 2000; 109:699-703.
3. Machin SJ, Mackie IJ, Guillebaud J. Factor V Leiden mutation, venous thromboembolism and combined oral contraceptive usage. Br J Fam Plann 1995; 21:13-14.
4. Martinelli I. Pros and cons of thrombophilia testing: pros. J Thromb Haemost 2003; 1:410-411.
5. Clark P, Twaddle S, Walker ID, et al. Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet 2002; 359:1919-1920.
6. Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999; 72:646-651.
7. Palareti G, Legnani C, Frascaro M, et al. Screening for activated protein C resistance before oral contraceptive treatment: a pilot study. Contraception 1999; 59:293-299.
8. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005; 131:80-90.
9. Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. Thromb Haemostat 2005; 94:17-25.
10. Machin SJ. Pros and cons of thrombophilia testing: cons. J Thromb Haemost 2003; 1:412-413.
11. Merriman L, Greaves M. Testing for thrombophilia: an evidence-based approach. Postgrad Med J 2006; 82:699-704. This is a comprehensive review and discussion on all the issues relating to thrombophilia testing.
12. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of healthcare programmes. Oxford: Oxford University Press, 1987.
13. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348:977-980.
14. Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314:796-800.
15. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362:428-432.
16. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, et al. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 1998; 147:387-390.
17. Lowe GD, Upton MN, Rumley A, et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein: a cross-sectional population survey. Thromb Haemost 2001; 86:550-556.